Zacks Investment Research downgraded shares of HUTCHISON CHINA/S (NASDAQ:HCM) from a hold rating to a sell rating in a report published on Wednesday.
According to Zacks, “Hutchison China MediTech Limited researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. The Company offers drugs for oncology and autoimmune diseases treatment. Hutchison China MediTech Limited is based in Hong Kong. “
Separately, BidaskClub cut HUTCHISON CHINA/S from a buy rating to a hold rating in a research note on Saturday, November 10th.
NASDAQ:HCM opened at $31.62 on Wednesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 4.55 and a current ratio of 4.67. HUTCHISON CHINA/S has a 52 week low of $25.76 and a 52 week high of $42.25. The firm has a market cap of $4.16 billion, a price-to-earnings ratio of -143.73 and a beta of 0.01.
A number of large investors have recently added to or reduced their stakes in the business. Royal Bank of Canada acquired a new stake in shares of HUTCHISON CHINA/S in the first quarter valued at $199,000. Millennium Management LLC acquired a new stake in shares of HUTCHISON CHINA/S in the first quarter valued at $1,009,000. Renaissance Technologies LLC raised its stake in shares of HUTCHISON CHINA/S by 375.0% in the third quarter. Renaissance Technologies LLC now owns 32,300 shares of the company’s stock valued at $1,040,000 after acquiring an additional 25,500 shares in the last quarter. State of New Jersey Common Pension Fund D acquired a new stake in shares of HUTCHISON CHINA/S in the second quarter valued at $2,651,000. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its stake in shares of HUTCHISON CHINA/S by 12.3% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 121,430 shares of the company’s stock valued at $3,660,000 after acquiring an additional 13,345 shares in the last quarter. Institutional investors own 11.79% of the company’s stock.
HUTCHISON CHINA/S Company Profile
Hutchison China MediTech Limited, a biopharmaceutical company, engages in the research, development, manufacture, and sale of pharmaceuticals and healthcare products primarily in the People's Republic of China and Hong Kong. It operates through Innovation Platform and Commercial Platform segments.
Further Reading: Asset Allocation, Balancing Your Investments
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for HUTCHISON CHINA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHISON CHINA/S and related companies with MarketBeat.com's FREE daily email newsletter.